Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/appi.ajp.2015.15101354 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Insomnia in Patients With Substance Use Disorders: Assessment and Management.
J Psychiatr Pract
January 2025
Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA.
Insomnia, characterized by difficulty initiating or maintaining sleep, or poor sleep quality, is highly prevalent among individuals with substance use disorders (SUDs). The relationship between the 2 conditions is often bidirectional. We reviewed the impact of various substances (alcohol, stimulants, opioids, and cannabis) on sleep architecture and their potential to contribute to insomnia.
View Article and Find Full Text PDFTapentadol Withdrawal Dystonia in a Young Adult Male Patient With Opioid Use Disorder.
J Clin Psychopharmacol
January 2024
Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bathinda, India
Mindfulness Training vs Recovery Support for Opioid Use, Craving, and Anxiety During Buprenorphine Treatment: A Randomized Clinical Trial.
JAMA Netw Open
January 2025
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.
Importance: During buprenorphine treatment for opioid use disorder (OUD), risk factors for opioid relapse or treatment dropout include comorbid substance use disorder, anxiety, or residual opioid craving. There is a need for a well-powered trial to evaluate virtually delivered groups, including both mindfulness and evidence-based approaches, to address these comorbidities during buprenorphine treatment.
Objective: To compare the effects of the Mindful Recovery Opioid Use Disorder Care Continuum (M-ROCC) vs active control among adults receiving buprenorphine for OUD.
Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies.
Cell Mol Life Sci
January 2025
Department of Psychiatry, Yale University School of Medicine, 300 George Street, Suite 901, New Haven, CT, 06511, USA.
The current opioid crisis has had an unprecedented public health impact. Approved medications for opioid use disorder (OUD) exist, yet their limitations indicate a need for innovative treatments. Limited preliminary clinical studies suggest specific psychedelics might aid OUD treatment, though most clinical evidence remains observational, with few controlled trials.
View Article and Find Full Text PDFPerinatal exposure to methadone or buprenorphine impairs hippocampal-dependent cognition and brain development in juvenile rats.
Prog Neuropsychopharmacol Biol Psychiatry
January 2025
School of Psychology, University of New South Wales, Sydney, Australia. Electronic address:
The opioid crisis continues to escalate, disproportionately affecting women of reproductive age. Traditionally the first line of treatment for pregnant women with opioid use disorder is the mu-opioid receptor agonist methadone. However, in recent years, the use of buprenorphine as a replacement therapy has increased as it has fewer side-effects and longer duration of action.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!